Enterprise Value
115.7M
Cash
87.02M
Avg Qtr Burn
-11.23M
Short % of Float
0.00%
Insider Ownership
0.00%
Institutional Own.
13.66%
Qtr Updated
12/31/22
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Lanifibranor (Pan-PPAR) Details Non-alcoholic steatohepatitis , Fatty liver disease, Liver disease | Phase 3 Data readout | |
Lanifibranor (Pan-PPAR) Details Non-alcoholic steatohepatitis , Fatty liver disease, Liver disease, Type 2 diabetes | Phase 2 Data readout | |
Lanifibranor + empagliflozin Details Non-alcoholic steatohepatitis , Fatty liver disease, Liver disease, Type 2 diabetes | Phase 2a Data readout | |
Cedirogant (ABBV-157) (60RORy) Details Psoriasis, Kidney cancer, Carcinoma | Failed Discontinued | |
Odiparcil (GAG) Details Rare diseases, Rare genetic disease, Mucopolysaccharidoses, Mucopolysaccharidosis type IV, Genetic disorder | Failed Discontinued |